EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials

Lowell L Hart, Seock-Ah Im, Sara M Tolaney, Mario Campone, Timothy Pluard, Berta Sousa, Gilles Freyer, Thomas Decker, Kevin Kalinsky, Gary Sopher, Melissa Gao, Huilin Hu und 1 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115225 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Lowell L Hart und 12 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic …. Hauptthemen laut MEDLINE: Breast Neoplasms, Purines, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPurinesAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsPatient Reported Outcome MeasuresHumansFemaleAgedMiddle AgedErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneAge FactorsAdultReceptors, EstrogenAged, 80 and overRandomized Controlled Trials as TopicAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

Age groupsBreast cancerCDK4/6 inhibitorsEfficacyPatient-reported outcomesSafety

Substanzen

PurinesAminopyridinesErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenAntineoplastic Agents, HormonalribociclibERBB2 protein, human

Autor:innen und Institutionen

  • Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: llhart@wakehealth.edu.
  • Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Dana-Farber Cancer Institute, Boston, MA, USA.
  • Institut de Cancérologie de l'Ouest/René Gauducheau Centre de Recherche en Cancérologie, St. Herblain, France.
  • Saint Luke's Cancer Institute, Kansas City, MO, USA.
  • Breast Unit, Champalimaud Clinical and Research Center/Champalimaud Foundation, Lisbon, Portugal.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Hart, L. L., Im, S. A., Tolaney, S. M., Campone, M., Pluard, T., Sousa, B., Freyer, G., Decker, T., Kalinsky, K., Sopher, G., Gao, M., Hu, H., & Kuemmel, S. (2025). Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115225

Vancouver

Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115225

BibTeX
@article{Hart2025,
  author = {Hart, Lowell L and Im, Seock-Ah and Tolaney, Sara M and Campone, Mario and Pluard, Timothy and Sousa, Berta and Freyer, Gilles and Decker, Thomas and Kalinsky, Kevin and Sopher, Gary and Gao, Melissa and Hu, Huilin and Kuemmel, Sherko},
  title = {Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115225}
}
Kostenlos starten →